Product Information
AVALIDE 150-12.5 MG TABLET is a brand product labeled by Sanofi-Aventis U.S. LLC, priced at $8.9109 per EA under NDC 00024585530. Its NADAC has been published 278 times since Nov 28, 2013.
FDA first approved this application on Sep 30, 1997. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the irbesartan and hydrochlorothiazide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
12.5; 150 mg/1; mg/1
Manufacturer
Sanofi-Aventis U.S. LLCNDC
00024585530
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
10/22/2025
Active Ingredients
HYDROCHLOROTHIAZIDE; IRBESARTANApproval Type
New Drug (NDA)
FDA Application
NDA020758FDA Approved
9/30/1997
TE Code
AB
On Market Since
1/1/2013
Pharmacological Classes
Price Statistics
The NADAC for AVALIDE 150-12.5 MG TABLET has been published 278 times since Nov 28, 2013, and over the history we have for it it has risen 134.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.9109 per EA |
|---|---|
| All-time high | $8.9109 (Aug 19, 2026) |
| All-time low | $3.7990 (Nov 28, 2013) |
| 52-week high | $8.9109 |
| 52-week low | $8.9109 |
| Median price | $6.6100 |
| Average price | $6.3739 |
| Largest weekly change | +26.8% (Sep 17, 2025) |
| Weeks tracked | 278 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the irbesartan and hydrochlorothiazide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of AVALIDE 150-12.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for AVALIDE 150-12.5 MG TABLET, manufactured by Sanofi-Aventis U.S. LLC, is $8.9109 per EA (NDC 00024585530), effective Aug 19, 2026.
How has the price of AVALIDE 150-12.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for AVALIDE 150-12.5 MG TABLET has risen 134.6%. It has been tracked across 278 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for AVALIDE 150-12.5 MG TABLET?
Since Nov 28, 2013, the NADAC for AVALIDE 150-12.5 MG TABLET has ranged from a low of $3.7990 (Nov 28, 2013) to a high of $8.9109 (Aug 19, 2026), with a median of $6.6100 per EA.
Are there cheaper alternatives to AVALIDE 150-12.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of AVALIDE 150-12.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AVALIDE 150-12.5 MG TABLET?
AVALIDE 150-12.5 MG TABLET (NDC 00024585530) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a brand product.